Chemotherapy TTNT analysis
| . | N . | Median TTNT (months) . | TTNT 95% CI (months) . | 1-y free from further treatment (%) . | 2-y free from further treatment (%) . | Median line of therapy . |
|---|---|---|---|---|---|---|
| All chemotherapy | 144 | 3.9 | 3.2-5.1 | 10.7 | 5.4 | 4 |
| Hyper CVAD | 13 | 5.0 | 2.6-5.5 | 7.7 | — | 2 |
| CHOP-like regimens | 28 | 5.7 | 2.3-7.7 | 14.3 | 14.3 | 2.5 |
| Non-CHOP “salvage” regimens* | 13 | 2.5 | 1.7-3.7 | 7.7 | — | 6 |
| Gemcitabine-based therapy | 30 | 4.0 | 3.0-5.7 | 11.1 | — | 5 |
| Fludarabine-based therapy | 8 | 2.3 | 0.3-7.4 | 12.5 | — | 5.5 |
| Chlorambucil | 14 | 4.8 | 2.1-9.0 | 21.4 | 21.4 | 2 |
| Cyclophosphamide-based therapy | 20 | 3.8 | 2.7-5.9 | 10.5 | — | 4 |
| Mitozantrone-based therapy | 3 | 5.8 | 2.5-N/A | 0 | 0 | 3 |
| Single-agent anthracycline | 6 | 1.8 | 0.7-N/A | — | — | 5 |
| Bendamustine | 1 | N/A | N/A | 0 | 0 | 4 |
| Etoposide | 3 | 3.2 | 1.6-N/A | 0 | 0 | 6 |
| Other purine analogs | 6 | 3.9 | 2.0-N/A | 0 | 0 | 7 |
| . | N . | Median TTNT (months) . | TTNT 95% CI (months) . | 1-y free from further treatment (%) . | 2-y free from further treatment (%) . | Median line of therapy . |
|---|---|---|---|---|---|---|
| All chemotherapy | 144 | 3.9 | 3.2-5.1 | 10.7 | 5.4 | 4 |
| Hyper CVAD | 13 | 5.0 | 2.6-5.5 | 7.7 | — | 2 |
| CHOP-like regimens | 28 | 5.7 | 2.3-7.7 | 14.3 | 14.3 | 2.5 |
| Non-CHOP “salvage” regimens* | 13 | 2.5 | 1.7-3.7 | 7.7 | — | 6 |
| Gemcitabine-based therapy | 30 | 4.0 | 3.0-5.7 | 11.1 | — | 5 |
| Fludarabine-based therapy | 8 | 2.3 | 0.3-7.4 | 12.5 | — | 5.5 |
| Chlorambucil | 14 | 4.8 | 2.1-9.0 | 21.4 | 21.4 | 2 |
| Cyclophosphamide-based therapy | 20 | 3.8 | 2.7-5.9 | 10.5 | — | 4 |
| Mitozantrone-based therapy | 3 | 5.8 | 2.5-N/A | 0 | 0 | 3 |
| Single-agent anthracycline | 6 | 1.8 | 0.7-N/A | — | — | 5 |
| Bendamustine | 1 | N/A | N/A | 0 | 0 | 4 |
| Etoposide | 3 | 3.2 | 1.6-N/A | 0 | 0 | 6 |
| Other purine analogs | 6 | 3.9 | 2.0-N/A | 0 | 0 | 7 |
Hyper CVAD Course A, cyclophosphamide, vincistrine, doxorubicin, dexamethasone; Hyper CVAD Course B, methotrexate, cytarabine; N/A, not able to be assessed.
Non-CHOP “salvage” regimens include: CMED (cyclophosphamide, methotrexate, etoposide, dexamethasone), DHAC (dexamethasone, doxorubicin, cytarabine, carboplatin), DHAP (dexamethasone, cytarabine, cisplatin), EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin), ICE (ifosfamide, carboplatin, etoposide), and Hi-DICE (dexamethasone, ifosfamide, cisplatin, etoposide).